Christopher J. Herrem, Ph.D.
Affiliations: | 2004 | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
Immunology, OncologyGoogle:
"Christopher Herrem"Parents
Sign in to add mentor| Walter J. Storkus | grad student | 2004 | University of Pittsburgh | |
| (Characterization and immune targeting of a novel tumor antigen, Epha2.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wesa AK, Herrem CJ, Mandic M, et al. (2008) Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. Journal of Immunology (Baltimore, Md. : 1950). 181: 7721-7 |
| Storkus WJ, Herrem C, Kawabe M, et al. (2007) Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. Critical Reviews in Immunology. 27: 485-93 |
| Herrem CJ, Tatsumi T, Olson KS, et al. (2005) Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 226-31 |
| Tatsumi T, Herrem CJ, Olson WC, et al. (2003) Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma Cancer Research. 63: 4481-4489 |